Tag: stock market

Netflix Inc. said Wednesday that it appointed Susan Rice, former U.S. National Security Advisor under President Obama, to its board of directors. Rice was also ambassador to the United Nations. “We are delighted to welcome Ambassador Rice to the Netflix board,” said Netflix Chief Executive Reed Hastings. “For decades, she has tackled difficult, complex global issues with intelligence, integrity and insight and we look forward to benefiting from her experience and wisdom.” Rice is currently a visiting research fellow at American University and a senior fellow at Harvard University. Netflix’s board currently has 11 members. The streaming video company’s stock was down 3.3% in midday trade, amid a broad selloff in the technology sector. It has run up 50.8% over the past three months, while the S&P 500 has slipped 2.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Netflix Inc. said Wednesday that it appointed Susan Rice, former U.S. National Security Advisor under President Obama, to its board of directors. Rice was also ambassador to the United Nations. “We are delighted to welcome Ambassador Rice to the Netflix board,” said Netflix Chief Executive Reed Hastings. “For decades, she has tackled difficult, complex global issues with intelligence, integrity and insight and we look forward to benefiting from her experience and wisdom.” Rice is currently a visiting research fellow at American University and a senior fellow at Harvard University. Netflix’s board currently has 11 members. The streaming video company’s stock was down 3.3% in midday trade, amid a broad selloff in the technology sector. It has run up 50.8% over the past three months, while the S&P 500 has slipped 2.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Equifax Inc. named Wednesday Mark Begor as its chief executive officer, effective April 16. Begor was most recently managing director at Warbug Pincus, and before that was at General Electric Co. for 35 years. He succeeds Paulino Do Rego Barros, who served as interim CEO since Sept. 26, 2017, when former CEO Richard Smith retired in the wake of a data breach scandal. The stock, which was still inactive in premarket trade, has lost 14.6% over the past 12 months, while the S&P 500 has gained 10.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of Edge Therapeutics Inc. plummeted 87% in active premarket trade toward a record low Wednesday, after an independent data monitoring committee recommended a phase 3 study of its treatment in adults with aneurysmal subarachnoid hemorrhage be stopped because data showing the trial had a “low probability” of meeting its primary endpoint. The stock was the most active ahead of the open with 2.1 million shares traded. Based on the committee’s recommendation, Edge said it has decided to discontinue the NEWTON 2 study. The company will analyst the data from the study to better understand the outcome. “We are very disappointed that the NEWTON 2 study did not demonstrate evidence of improved outcomes with EG-1962, given the positive findings demonstrated on this measure in our randomized, open-label Phase 1/2 NEWTON study of EG-1962 in a similar patient population,” said Chief Executive Brian Leuthner. The stock, which went public Oct. 1, 2015 at an initial public offering price of $11, had soared 94% over the past 12 months through Tuesday, while the iShares Nasdaq Biotechnology ETF had climbed 8.0% and the S&P 500 had gained 11%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of Edge Therapeutics Inc. plummeted 87% in active premarket trade toward a record low Wednesday, after an independent data monitoring committee recommended a phase 3 study of its treatment in adults with aneurysmal subarachnoid hemorrhage be stopped because data showing the trial had a “low probability” of meeting its primary endpoint. The stock was the most active ahead of the open with 2.1 million shares traded. Based on the committee’s recommendation, Edge said it has decided to discontinue the NEWTON 2 study. The company will analyst the data from the study to better understand the outcome. “We are very disappointed that the NEWTON 2 study did not demonstrate evidence of improved outcomes with EG-1962, given the positive findings demonstrated on this measure in our randomized, open-label Phase 1/2 NEWTON study of EG-1962 in a similar patient population,” said Chief Executive Brian Leuthner. The stock, which went public Oct. 1, 2015 at an initial public offering price of $11, had soared 94% over the past 12 months through Tuesday, while the iShares Nasdaq Biotechnology ETF had climbed 8.0% and the S&P 500 had gained 11%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of bluebird bio Inc. climbed 2.6% in premarket trade Wednesday, after the gene therapy company announced an agreement with Celgene Corp. to co-develop and promote bb2121, an investigation therapy for the potential treatment of multiple myeloma. The companies had originally entered a research collaboration in 2013 to discover, develop and commercialize oncology therapies, including bb2121. “We are extremely pleased to advance our collaboration with bluebird on bb2121 and we believe this therapy has the potential to significantly impact the treatment approach and outcomes for patients with multiple myeloma,” said Nadim Ahmed, president of hematology and oncology for Celgene. Bluebird’s stock has lost 2.5% over the past three months and Celgene shares have tumbled 18.1%, while the iShares Nasdaq Biotechnology ETF has declined 2.5% and the S&P 500 has slipped 2.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News